These findings reinforce the renal protective effects of SGLT2 inhibitors in MRL/lpr mice and provide further evidence supporting the potential of non-immunosuppressive therapies to enhance renal function in autoimmune nephropathies such as lupus. This evidence concerns the gene SLC5A2 and systemic lupus erythematosus.